Intrahepatic Cholangiocarcinoma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Basilea Pharmaceutica, Virogin Biotech Ltd, TriSalus Life Sciences, Forma Therapeuti

Intrahepatic Cholangiocarcinoma Pipeline constitutes 18+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analyzes DelveInsight.

Intrahepatic Cholangiocarcinoma Overview:

Intrahepatic cholangiocarcinoma (ICC) is the second most prevalent liver malignancy, accounting for about 10% of all cholangiocarcinomas. It originates in the peripheral bile ducts within the liver parenchyma, near the secondary biliary radicals. Most ICCs are histologically classified as adenocarcinomas and typically develop as well-differentiated adenocarcinomas. The formation of ICC is often driven by mutations in the KRAS oncogene, which plays a role in cell proliferation, alongside the deletion of the p53 tumor suppressor gene. The American Joint Committee on Cancer (AJCC) TNM staging system, now in its seventh edition, is the most widely used method to assess the progression and resectability of ICC, with four stages.

Request for a detailed insights report on Intrahepatic Cholangiocarcinoma pipeline insights @ https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Intrahepatic Cholangiocarcinoma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Intrahepatic Cholangiocarcinoma Therapeutics Market.

Key Takeaways from the Intrahepatic Cholangiocarcinoma Pipeline Report

DelveInsight's Intrahepatic Cholangiocarcinoma pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Intrahepatic Cholangiocarcinoma treatment.
In January 2022, the US FDA approved the Investigational New Drug (IND) application for KIN-3248, a next-generation pan-FGFR inhibitor being developed by Kinnate Biopharma for intrahepatic cholangiocarcinoma.
In February 2022, HUTCHMED launched a Phase Ib/II study in China to evaluate HMPL-453 in combination with chemotherapy or Toripalimab for advanced solid tumors, including intrahepatic cholangiocarcinoma. HMPL-453 is also being tested as a monotherapy in a Phase II clinical trial in China.
In May 2021, Kinnate Biopharma Inc. secured USD 35 million in Series A financing to establish a joint venture in China. The venture aims to advance the development of KIN-3248 for the Chinese market. KIN-3248 is an FGFR inhibitor candidate designed to treat patients with intrahepatic cholangiocarcinoma (ICC).
Key Intrahepatic Cholangiocarcinoma companies such as Basilea Pharmaceutica, Virogin Biotech Ltd, TriSalus Life Sciences, Forma Therapeutics, Inc, Kinnate Biopharma, Relay Therapeutics, ABL Bio, Hutchison MediPharma, Sirnaomics, Jiangsu Hengrui Medicine, and others are evaluating new drugs for Intrahepatic Cholangiocarcinoma to improve the treatment landscape.
Promising Intrahepatic Cholangiocarcinoma pipeline therapies in various stages of development include Derazantinib, and others.

Intrahepatic Cholangiocarcinoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Intrahepatic Cholangiocarcinoma Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Intrahepatic Cholangiocarcinoma treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Intrahepatic Cholangiocarcinoma market.

Download our free sample page report on Intrahepatic Cholangiocarcinoma pipeline insights @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Intrahepatic Cholangiocarcinoma Emerging Drugs

Derazantinib: Basilea Pharmaceutica

Intrahepatic Cholangiocarcinoma Companies

Over 18 major companies are working on developing therapies for intrahepatic cholangiocarcinoma. Among them, Basilea Pharmaceutica has drug candidates for intrahepatic cholangiocarcinoma in the most advanced stage, namely Phase II.

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Intrahepatic Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Intrahepatic Cholangiocarcinoma Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Intrahepatic Cholangiocarcinoma Therapies and Key Companies: Intrahepatic Cholangiocarcinoma Clinical Trials and advancements @ https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Intrahepatic Cholangiocarcinoma Pipeline Therapeutic Assessment
• Intrahepatic Cholangiocarcinoma Assessment by Product Type
• Intrahepatic Cholangiocarcinoma By Stage
• Intrahepatic Cholangiocarcinoma Assessment by Route of Administration
• Intrahepatic Cholangiocarcinoma Assessment by Molecule Type

Download Intrahepatic Cholangiocarcinoma Sample report to know in detail about the Intrahepatic Cholangiocarcinoma treatment market @ Intrahepatic Cholangiocarcinoma Therapeutic Assessment @ https://www.delveinsight.com/sample-request/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Intrahepatic Cholangiocarcinoma Current Treatment Patterns
4. Intrahepatic Cholangiocarcinoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Intrahepatic Cholangiocarcinoma Late-Stage Products (Phase-III)
7. Intrahepatic Cholangiocarcinoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Intrahepatic Cholangiocarcinoma Discontinued Products
13. Intrahepatic Cholangiocarcinoma Product Profiles
14. Intrahepatic Cholangiocarcinoma Key Companies
15. Intrahepatic Cholangiocarcinoma Key Products
16. Dormant and Discontinued Products
17. Intrahepatic Cholangiocarcinoma Unmet Needs
18. Intrahepatic Cholangiocarcinoma Future Perspectives
19. Intrahepatic Cholangiocarcinoma Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Intrahepatic Cholangiocarcinoma Pipeline Reports Offerings: https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-icc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.